Medibio Ltd
ASX:MEB
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| AU |
|
Medibio Ltd
ASX:MEB
|
122m AUD |
Loading...
|
|
| US |
C
|
Cerner Corp
LSE:0R00
|
31.3B USD |
Loading...
|
|
| US |
|
Veeva Systems Inc
NYSE:VEEV
|
30.2B USD |
Loading...
|
|
| AU |
|
Pro Medicus Ltd
ASX:PME
|
16.4B AUD |
Loading...
|
|
| JP |
|
M3 Inc
TSE:2413
|
1.2T JPY |
Loading...
|
|
| US |
|
Doximity Inc
NYSE:DOCS
|
5.2B USD |
Loading...
|
|
| SE |
|
Sectra AB
STO:SECT B
|
40.1B SEK |
Loading...
|
|
| US |
W
|
Waystar Holding Corp
NASDAQ:WAY
|
4.2B USD |
Loading...
|
|
| CN |
|
Winning Health Technology Group Co Ltd
SZSE:300253
|
24.5B CNY |
Loading...
|
|
| IN |
I
|
Inventurus Knowledge Solutions Ltd
NSE:IKS
|
288.2B INR |
Loading...
|
|
| US |
V
|
Vocera Communications Inc
F:V00
|
2.4B EUR |
Loading...
|
Market Distribution
| Min | -16 177 900% |
| 30th Percentile | -544.7% |
| Median | -27.7% |
| 70th Percentile | 3.1% |
| Max | 3 174 540% |
Other Profitability Ratios
Medibio Ltd
Glance View
Medibio Ltd. engages in the clinical research, product development and early stage commercialization of a mental health technology. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2001-01-29. The firm offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company offers a software called MEBsleep, a medical device that analyses Electroencephalogram (EEG) and Electrocardiogram (ECG) data collected during polysomnography to verify sleep stages and heart rate variability (HRV) in patients suffering from primary or secondary sleep disturbances. The Company’s subsidiaries include Bioprospect Australia Pty Ltd, Australian Phytochemicals Pty Ltd, BioProspect America Pty Ltd, Medibio Limited USA, Invatec Health Pty Ltd and Annapanna Pty Ltd.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Medibio Ltd is -323.7%, which is in line with its 3-year median of -323.7%.
Over the last 3 years, Medibio Ltd’s Net Margin has increased from -415.1% to -323.7%. During this period, it reached a low of -1 262% on Dec 31, 2022 and a high of -114.1% on Dec 31, 2021.
